Every 8-K that Kezar Life Sciences, Inc. (KZR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KZR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KZR filings page.
Kezar Life Sciences has been acquired by Aurinia Pharma U.S. through a tender offer and follow-on merger. Stockholders receive $6.955 in cash per share plus one contingent value right (CVR) for each share, giving potential additional cash payments under a CVR agreement.
At expiration of the offer, 5,927,580 shares, or about 80.2% of outstanding shares, were validly tendered, satisfying the minimum condition. Merger Sub then merged into Kezar under Section 251(h) of Delaware law, making Kezar a wholly owned subsidiary of Aurinia.
Trading in KZR common stock is being suspended, and Kezar is being delisted from Nasdaq, with plans to terminate SEC registration and reporting. The prior board resigned, and Aurinia’s designees, led by Kevin Tang, became the sole director and officers of the surviving corporation.
Kezar Life Sciences, Inc. has terminated its headquarters lease early and announced leadership changes in connection with a pending sale. The company ended its lease for approximately 48,714 rentable square feet at 4000 Shoreline Court effective April 1, 2026, agreeing to pay the landlord about $2 million, including about $1.3 million in cash and surrender of about $0.7 million in security deposit.
On the same date, Kezar entered into separation agreements with its Chief Executive Officer Christopher J. Kirk, Ph.D., Chief Financial Officer and Secretary Marc L. Belsky, and Chief Operating Officer Mark Schiller, providing change-in-control style severance benefits and noting there were no disagreements with the company.
The filing also reiterates a previously announced Merger Agreement under which a subsidiary of Aurinia Pharma U.S., Inc. plans a tender offer in which each outstanding Kezar share would be converted into the right to receive $6.955 in cash plus one contingent value right, subject to the terms and conditions of the proposed transaction and related tender offer materials.
Kezar Life Sciences agreed to be acquired by Aurinia Pharma U.S. through a cash tender offer followed by a merger. Aurinia will offer $6.955 in cash per Kezar share plus one contingent value right (CVR), giving stockholders potential additional cash tied to Kezar legacy assets and net cash above $50 million.
The tender offer will be launched within ten business days and kept open for 20 business days, with closing targeted for the second quarter of 2026, if customary conditions are met. A major stockholder holding about 9.0% of Kezar shares has agreed to tender, and Kezar’s board unanimously determined the deal is in the best interests of stockholders.
Kezar Life Sciences has sold its Sec61-based discovery and development program, including preclinical candidate KZR-261, to Enodia Therapeutics. Kezar received $800,000 at closing and is due an additional $200,000 tied to delivery of inventory or 45 days after closing.
The deal also includes up to $127,000,000 in development, regulatory and commercial milestone payments, plus single digit tiered royalties on future net sales of products derived from the acquired assets. Enodia assumed specified liabilities linked to transferred contracts and the acquired assets, while both parties agreed to customary indemnification capped at $1,000,000 for non-fraud losses.
The transaction carves out only the Sec61 program; Kezar retained its zetomipzomib program, employee contracts, cash, receivables, real property and equipment. A joint press release announcing the deal was issued on March 12, 2026.
Kezar Life Sciences (KZR) announced a major restructuring, reducing its workforce by approximately 31 employees, or about 70%, in connection with its evaluation of strategic alternatives.
The company estimates cash expenditures of about $6.0 million for one-time severance, benefits, and related costs, with the majority of these charges expected to be recognized in the fourth quarter of 2025. Management noted that actual costs could differ materially and that additional charges may arise depending on subsequent events.
Kezar Life Sciences (KZR) repaid its debt under a prior loan agreement and terminated the facility. On October 20, 2025, the company used cash on hand to repay $6.3 million, covering the aggregate outstanding amount, accrued interest, and exit fees under its November 4, 2021 Loan and Security Agreement with Oxford Finance LLC and related lenders. Following repayment, the agreement was terminated and all liens and security interests were released.
This action removes obligations tied to the loan and releases collateral, simplifying Kezar’s capital structure.
Kezar Life Sciences (KZR) disclosed two actions. The company announced a regulatory update on its zetomipzomib program in autoimmune hepatitis and said it plans to explore strategic alternatives. It also reported preliminary cash, cash equivalents and marketable securities of $90.2 million as of September 30, 2025.
The company entered into Amendment No. 2 to its Rights Agreement. The amendment extends the Final Expiration Date to the day following certification of voting results at the 2026 annual meeting, or, if stockholders approve or ratify the Rights Agreement at that meeting, to the day following certification of voting results at the 2027 annual meeting, unless the Rights are earlier redeemed or exchanged.
Kezar Life Sciences reported it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The current report furnishes that press release as Exhibit 99.1 and incorporates it by reference. The filing also includes a Cover Page Interactive Data File as Exhibit 104.
The company states that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated. No additional financial detail or analysis is included within this report.
Kezar Life Sciences (Nasdaq: KZR) filed a Form 8-K disclosing the voting results of its 17 June 2025 annual meeting (Item 5.07).
Shareholders elected three Class I directors to serve until the 2028 meeting: Elizabeth Garner, M.D. (2,148,505 for / 1,793,162 withheld), Michael Kauffman, M.D., Ph.D. (1,618,735 for / 2,322,932 withheld) and Courtney Wallace (1,551,353 for / 2,390,314 withheld).
The meeting also approved, on an advisory basis, executive compensation (2,151,745 for; 1,781,942 against; 7,980 abstain) and ratified KPMG LLP as independent auditor for fiscal 2025 (6,116,820 for; 56,801 against; 8,526 abstain).
No financial performance updates, strategic announcements or other material events were included.